Tofacitinib Treatment in Patients With Active COVID-19 Infection

    September 2021 in “ Curēus
    Abdulmajeed Alajlan, Lama Alzamil, Amal M Aseri
    Image of study
    TLDR Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
    The document discusses the use of tofacitinib, a JAK1 and JAK3 inhibitor, in treating alopecia areata, an autoimmune disorder causing hair loss. Tofacitinib has been shown to be effective in promoting hair regrowth in patients with this condition. Despite concerns about potential immunosuppression during active COVID-19 infections, the document reports on two cases where patients with alopecia universalis continued their tofacitinib treatment without experiencing any worsening of their COVID-19 symptoms. This suggests that tofacitinib may be safely used without adverse effects on the course of COVID-19, although the sample size is very small with only two cases.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 6 results

    Related Research

    1 / 1 results